These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. Barchetta I; Ceccarelli V; Cimini FA; Bertoccini L; Fraioli A; Alessandri C; Lenzi A; Baroni MG; Cavallo MG J Endocrinol Invest; 2019 May; 42(5):513-520. PubMed ID: 30132286 [TBL] [Abstract][Full Text] [Related]
10. Polymorphism rs2073618 of the osteoprotegerin gene as a potential marker of subclinical carotid atherosclerosis in Caucasians with type 2 diabetes mellitus. Pleskovič A; Ramuš SM; Pražnikar ZJ; Šantl Letonja M; Cokan Vujkovac A; Gazdikova K; Caprnda M; Gaspar L; Kruzliak P; Petrovič D Vasa; 2017 Aug; 46(5):355-362. PubMed ID: 28593808 [TBL] [Abstract][Full Text] [Related]
11. Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease. Bozic M; Méndez-Barbero N; Gutiérrez-Muñoz C; Betriu A; Egido J; Fernández E; Martín-Ventura JL; Valdivielso JM; Blanco-Colio LM; Atherosclerosis; 2018 Mar; 270():13-20. PubMed ID: 29407881 [TBL] [Abstract][Full Text] [Related]
12. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Stępień E; Wypasek E; Stopyra K; Konieczyńska M; Przybyło M; Pasowicz M Clin Biochem; 2011 Jul; 44(10-11):826-31. PubMed ID: 21539822 [TBL] [Abstract][Full Text] [Related]
13. Elevated osteopontin levels in patients with peripheral arterial disease. Koshikawa M; Aizawa K; Kasai H; Izawa A; Tomita T; Kumazaki S; Tsutsui H; Koyama J; Shimodaira S; Takahashi M; Ikeda U Angiology; 2009; 60(1):42-5. PubMed ID: 18388057 [TBL] [Abstract][Full Text] [Related]
14. The Emerging Role of Bone Markers in Diagnosis and Risk Stratification of Patients With Coronary Artery Disease. Kosmopoulos M; Paschou SA; Grapsa J; Anagnostis P; Vryonidou A; Goulis DG; Siasos G Angiology; 2019 Sep; 70(8):690-700. PubMed ID: 30696256 [TBL] [Abstract][Full Text] [Related]
15. Association of serum levels of osteopontin and osteoprotegerin with adverse outcomes after endovascular revascularisation in peripheral artery disease. Kadoglou NPE; Kapetanios D; Korakas E; Valsami G; Tentolouris N; Papanas N; Lambadiari V; Karkos C Cardiovasc Diabetol; 2022 Sep; 21(1):171. PubMed ID: 36050687 [TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin SNP associations with coronary artery disease and ischemic stroke risk: a meta-analysis. Wu J; Li X; Gao F; Gao S; Lyu J; Qiang H Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32955093 [TBL] [Abstract][Full Text] [Related]
17. Osteopontin and osteoprotegerin levels in type 2 diabetes and their association with cardiovascular autonomic function. Maser RE; Lenhard MJ; Pohlig RT; Balagopal PB J Diabetes Complications; 2016 Apr; 30(3):507-10. PubMed ID: 26775555 [TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin and Osteopontin Serum Levels are Associated with Vascular Function and Inflammation in Coronary Artery Disease Patients. Maniatis K; Siasos G; Oikonomou E; Vavuranakis M; Zaromytidou M; Mourouzis K; Paraskevopoulos T; Charalambous G; Papavassiliou AG; Tousoulis D Curr Vasc Pharmacol; 2020; 18(5):523-530. PubMed ID: 31642412 [TBL] [Abstract][Full Text] [Related]
19. Interdependence between osteoprotegerin and active von Willebrand factor in long-term cardiovascular mortality prediction in patients undergoing percutaneous coronary intervention. Siller-Matula J; Lang IM; Schoergenhofer C; Roest M; Jilma B Thromb Haemost; 2017 Aug; 117(9):1730-1738. PubMed ID: 28726980 [TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin as a marker of atherosclerosis: a systematic update. Hosbond SE; Poulsen TS; Diederichsen AC; Nybo M; Rasmussen LM; Mickley H Scand Cardiovasc J; 2012 Aug; 46(4):203-11. PubMed ID: 22506827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]